Cargando…

The Origin and Biomedical Relevance of Cannabigerol

The constant search for new pharmacologically active compounds, especially those that do not exhibit toxic effects, intensifies the interest in plant-based ingredients and their potential use in pharmacotherapy. One of the plants that has great therapeutic potential is Cannabis sativa L., a source o...

Descripción completa

Detalles Bibliográficos
Autores principales: Jastrząb, Anna, Jarocka-Karpowicz, Iwona, Skrzydlewska, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322760/
https://www.ncbi.nlm.nih.gov/pubmed/35887277
http://dx.doi.org/10.3390/ijms23147929
_version_ 1784756384069320704
author Jastrząb, Anna
Jarocka-Karpowicz, Iwona
Skrzydlewska, Elżbieta
author_facet Jastrząb, Anna
Jarocka-Karpowicz, Iwona
Skrzydlewska, Elżbieta
author_sort Jastrząb, Anna
collection PubMed
description The constant search for new pharmacologically active compounds, especially those that do not exhibit toxic effects, intensifies the interest in plant-based ingredients and their potential use in pharmacotherapy. One of the plants that has great therapeutic potential is Cannabis sativa L., a source of the psychoactive Δ(9)-tetrahydrocannabinol (Δ(9)-THC), namely cannabidiol (CBD), which exhibits antioxidant and anti-inflammatory properties, and cannabigerol (CBG)—a biologically active compound that is present in much smaller quantities. CBG is generated during the non-enzymatic decarboxylation of cannabigerolic acid, a key compound in the process of biosynthesis of phytocannabinoids and consequently the precursor to various phytocannabinoids. By interacting with G-protein-coupled receptors, CBG exhibits a wide range of biological activities, inter alia, anti-inflammatory, antibacterial and antifungal activities, regulation of the redox balance, and neuromodulatory effects. Due to the wide spectrum of biological activities, CBG seems to be a very promising compound to be used in the treatment of diseases that require multidirectional pharmacotherapy. Moreover, it is suggested that due to the relatively rapid metabolism of cannabigerol, determination of the concentration of the phytocannabinoid in blood or oral fluid can be used to determine cannabis use. Therefore, it seems obvious that new therapeutic approaches using CBG can be expected.
format Online
Article
Text
id pubmed-9322760
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93227602022-07-27 The Origin and Biomedical Relevance of Cannabigerol Jastrząb, Anna Jarocka-Karpowicz, Iwona Skrzydlewska, Elżbieta Int J Mol Sci Review The constant search for new pharmacologically active compounds, especially those that do not exhibit toxic effects, intensifies the interest in plant-based ingredients and their potential use in pharmacotherapy. One of the plants that has great therapeutic potential is Cannabis sativa L., a source of the psychoactive Δ(9)-tetrahydrocannabinol (Δ(9)-THC), namely cannabidiol (CBD), which exhibits antioxidant and anti-inflammatory properties, and cannabigerol (CBG)—a biologically active compound that is present in much smaller quantities. CBG is generated during the non-enzymatic decarboxylation of cannabigerolic acid, a key compound in the process of biosynthesis of phytocannabinoids and consequently the precursor to various phytocannabinoids. By interacting with G-protein-coupled receptors, CBG exhibits a wide range of biological activities, inter alia, anti-inflammatory, antibacterial and antifungal activities, regulation of the redox balance, and neuromodulatory effects. Due to the wide spectrum of biological activities, CBG seems to be a very promising compound to be used in the treatment of diseases that require multidirectional pharmacotherapy. Moreover, it is suggested that due to the relatively rapid metabolism of cannabigerol, determination of the concentration of the phytocannabinoid in blood or oral fluid can be used to determine cannabis use. Therefore, it seems obvious that new therapeutic approaches using CBG can be expected. MDPI 2022-07-19 /pmc/articles/PMC9322760/ /pubmed/35887277 http://dx.doi.org/10.3390/ijms23147929 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jastrząb, Anna
Jarocka-Karpowicz, Iwona
Skrzydlewska, Elżbieta
The Origin and Biomedical Relevance of Cannabigerol
title The Origin and Biomedical Relevance of Cannabigerol
title_full The Origin and Biomedical Relevance of Cannabigerol
title_fullStr The Origin and Biomedical Relevance of Cannabigerol
title_full_unstemmed The Origin and Biomedical Relevance of Cannabigerol
title_short The Origin and Biomedical Relevance of Cannabigerol
title_sort origin and biomedical relevance of cannabigerol
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322760/
https://www.ncbi.nlm.nih.gov/pubmed/35887277
http://dx.doi.org/10.3390/ijms23147929
work_keys_str_mv AT jastrzabanna theoriginandbiomedicalrelevanceofcannabigerol
AT jarockakarpowicziwona theoriginandbiomedicalrelevanceofcannabigerol
AT skrzydlewskaelzbieta theoriginandbiomedicalrelevanceofcannabigerol
AT jastrzabanna originandbiomedicalrelevanceofcannabigerol
AT jarockakarpowicziwona originandbiomedicalrelevanceofcannabigerol
AT skrzydlewskaelzbieta originandbiomedicalrelevanceofcannabigerol